Home › NDC Lookup › Ingredients › Carboxymethylcellulose Sodium And Glycer... › 00023-3240-15
REFRESH OPTIVE carboxymethylcellulose sodium and glycerin 5 mg/mL; 9 mg/mL Solution/ Drops — NDC 00023-3240-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

REFRESH OPTIVE carboxymethylcellulose sodium and glycerin 5 mg/mL; 9 mg/mL Solution/ Drops — NDC 0023-3240-15 (Billing 00023-3240-15)

by Allergan, Inc. · 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER

This is a package of REFRESH OPTIVE carboxymethylcellulose sodium and glycerin 5 mg/mL; 9 mg/mL Solution/ Drops from Allergan, Inc., marketed since Sep 2006 and currently FDA-listed; retail pharmacies pay about $0.6591 per mL (NADAC). It is the main listing for this product, which comes in 4 package sizes.

NDC 00023-3240-15
🏷️ FDA NDC (as labeled) 0023-3240-15 billing pads the labeler segment with a zero
This package
Contains15 mL in 1 bottle, dropper Cost per mL$0.6591 NADAC Per package$9.89 / 15 ml Pack sizes4 compare ↓
Also priced by: Medicaid pays $1.25/unit — full pricing hub ↓
Main listing for product 0023-3240 · Also comes in: 2 mL 0023-3240-02 3 mL 0023-3240-03 2 bottles 0023-3240-01
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0023-3240-15 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0023 labeler · 3240 product · 15 package
Package marketed since
Sep 6, 2006
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0023324015 1
Medicaid fills, this package
155,152 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0023-3240-15
Product NDC 0023-3240
11-digit billing NDC 00023324015
NCPDP billing unit ML — per mL (volume)
RxCUI 1100650
UNII K679OBS311, PDC6A3C0OX
Application # M018
SPL Set ID 7f8d88af-fd3b-4138-af61-f24c59ccebd7
Established class (EPC) Non-Standardized Chemical Allergen
Physiologic effect Increased Histamine Release; Cell-mediated Immunity; Increased IgG Production
Chemical class Allergens; Glycerol
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2006-09-06
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance CARBOXYMETHYLCELLULOSE SODIUM; GLYCERIN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86209902122010
GPI class Refresh Optive
GCN Seq No 062806
GCN 98577
HICL code 034858
Ingredient (HICL) Carboxymethylcellulos/Glycerin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6T
Therapeutic class — specific (HIC3) Artificial Tears
AHFS code 52:92.00.00
AHFS class Eent Drugs, Miscellaneous
FDB label name REFRESH OPTIVE EYE DROPS
FDB brand name Refresh Optive
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 062806
  • GCN: 98577
  • GPI-14 (Medi-Span): 86209902122010
  • HICL (First Databank): 034858
  • AHFS class code: 52:92.00.00
  • RxCUI (RxNorm): 1100650
Why two NDCs? The FDA registers this code as 0023-3240-15 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00023-3240-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name REFRESH OPTIVE EYE DROPS Ingredient Carboxymethylcellulos/Glycerin
🧪 What is this product?

Refresh Optive is an over-the-counter eye drop solution containing two lubricating agents: carboxymethylcellulose sodium and glycerin. These ingredients are typically used together to help moisturize and protect the surface of the eye. This product is formulated as an ophthalmic solution applied directly to the eye and is marketed under FDA's over-the-counter monograph rules for lubricating eye drops.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.659 $9.89 / 15 ml
Medicaid paysCMS SDUD · 12 mo $1.25 $18.80 / 15 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Feb 2026 Apr 2026 Aug 2026 $0.707 $0.659
Flat over the last 8 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00023-3240-01 0023-3240-01 2 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER — — 2006-09-06 — Discontinued by firm
00023-3240-02 0023-3240-02 1 BOTTLE, DROPPER in 1 CARTON / 2 mL in 1 BOTTLE, DROPPER — — 2006-09-06 — Discontinued by firm
00023-3240-03 0023-3240-03 1 BOTTLE, DROPPER in 1 CARTON / 3 mL in 1 BOTTLE, DROPPER — — 2006-09-06 — Discontinued by firm
00023-3240-15 You're viewing this Main listing 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER $0.6591 / mL $9.89 2006-09-06 — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 bottle, dropper in 1 carton / 15 ml in 1 bottle, dropper.
What NDC number is used to bill for this package of REFRESH OPTIVE carboxymethylcellulose sodium and glycerin 5 mg/mL; 9 mg/mL Solution/ Drops?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Refresh RELIEVA PF 5 mg/mL; 10 mg/mL 00023-4515-30 Allergan, 30 vials $0.453 — Availability likely save 31%
Refresh Optive 5 mg/mL; 9 mg/mLthis 00023-3240-15 Allergan, 1 bottle $0.659 — Availability likely —
Refresh Tears Pf 5 mg/mL; 9 mg/mL 00023-3110-10 Allergan, 1 bottle $1.254 — Availability likely +90%
Refresh Relieva PF Xtra 5 mg/mL; 9 mg/mL 00023-3782-10 Allergan, 1 bottle $1.254 — Availability likely +90%
Refresh Optive 5 mg/mL; 9 mg/mL 00023-3416-05 Allergan, 5 vials — — FDA listed —
Refresh Relieva 5 mg/mL; 9 mg/mL 00023-6630-03 Allergan, 1 bottle — — FDA listed —
Refresh Relieva Preservative Free 5 mg/mL; 9 mg/mL 00023-6634-01 Allergan, 1 bottle — — FDA listed —
Equate Lubricant Eye Drops .5 g/100mL; .9 g/100mL 11716-0365-05 Hanlim 1 bottle — — FDA listed —
Medics Choice Fresh and Soothe 5 mg/mL; 9 mg/mL 55651-0200-01 KC 1 bottle — — FDA listed —
Medics Choice Fresh and Soothe 5 mg/mL; 9 mg/mL 73669-0200-01 Unimed 1 bottle — — FDA listed —
Equate Optimal Hydration Lubricant Eye Drops .5 g/100mL; .9 g/100mL 79903-0258-05 Walmart, 1 bottle — — FDA listed —
Equate Lubricant Eye Drops .5 g/100mL; .9 g/100mL 79903-0365-05 Walmart 1 bottle — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2006
On the market since
Sep 2006
📍
2026
Currently FDA-listed
20 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAllergan, Inc.
FDA applicationM018 (OTC MONOGRAPH DRUG)
Labeler code00023
First marketedSep 2006
Product typeHuman Otc Drug
Portfolio188 products on file

More NDCs from Allergan, Inc. labeler code 00023

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 31 words ▾

Uses For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. May be used as a protectant against further irritation.

⏱️ Dosage and Administration 12 words ▾

Directions Instill 1 or 2 drops in the affected eye(s) as needed.

⚠️ Warnings 84 words ▾

Warnings For external use only. To avoid contamination, do not touch tip of container to any surface. Replace cap after using.

If solution changes color or becomes cloudy, d o not use. Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours. Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 7 words ▾

Active ingredients Carboxymethylcellulose sodium 0.5% Glycerin 0.9%

🧪 Inactive Ingredients 28 words ▾

Inactive ingredients Boric acid; calcium chloride dihydrate; erythritol; levocarnitine; magnesium chloride hexahydrate; potassium chloride; purified water; PURITE ® (stabilized oxychloro complex); sodium borate decahydrate; and sodium citrate dihydrate.

🎯 Purpose 5 words ▾

Purpose Eye lubricant Eye lubricant

📄 Stop Use and Ask a Doctor If 33 words ▾

Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 36 words ▾

Other information Use only if tape seals on top and bottom flaps are intact. Use before expiration date marked on container. Discard 90 days after opening. Store at 59°-77°F (15°-25°C). RETAIN THIS CARTON FOR FUTURE REFERENCE.

📄 Questions or Comments 6 words ▾

Questions or comments? 1.800.678.1605 refreshbrand.com v1.0DFL3240

📄 Package Label / Principal Display Panel 48 words ▾

PRINCIPAL DISPLAY PANEL 0023-3240-15 Refresh Optive ® Lubricant Eye Drops DUAL-ACTION RELIEF L ubricat es & H ydrat es Dry, Irritated Eyes 0.5 fl oz (15 mL) Sterile 0023-3240-15 Refresh Optive® Lubricant Eye Drops DUAL-ACTION RELIEF Lubricates and hydrates Dry, Irritated Eyes 0.5 fl oz (15 mL) Sterile

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
155.2K
Units reimbursed last 4 qtrs
2.4M
Gross reimbursed last 4 qtrs
$3.06M
Avg / prescription
$19.69
Avg / unit
$1.2530
Latest quarter Q1 2026
37.6KRx
Medicaid pays / mL
$1.2530
gross reimbursed
vs
NADAC / mL
$0.6591
acquisition cost
=
Spread
+$0.5939
+90% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
97% FFS
Fee-for-service · 150,797 Rx Managed care · 4,355 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 29,205 units · 509 per 100k residents MN Wisconsin: no data reported WI Michigan: 735 units · 7.3 per 100k residents MI New York: 2,342,478 units · 11,969 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 1,305 units · 30.8 per 100k residents OR Nevada: 1,065 units · 33.3 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 1,050 units · 8.4 per 100k residents IL Indiana: 10,400 units · 152 per 100k residents IN Ohio: no data reported OH Pennsylvania: 27,790 units · 214 per 100k residents PA New Jersey: 1,065 units · 11.5 per 100k residents NJ Massachusetts: no data reported MA California: 10,470 units · 26.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 1,215 units · 61.4 per 100k residents NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 1,200 units · 13.8 per 100k residents VA Maryland: no data reported MD Connecticut: 6,195 units · 171 per 100k residents CT Rhode Island: 735 units · 67.1 per 100k residents RI Arizona: no data reported AZ New Mexico: 1,090 units · 51.6 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: 2,610 units · 48.6 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
7.311,969
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 11,969 /100k
2 Minnesota 509 /100k
3 Pennsylvania 214 /100k
4 Connecticut 171 /100k
5 Indiana 152 /100k
6 Rhode Island 67.1 /100k
7 Nebraska 61.4 /100k
8 New Mexico 51.6 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 bottle this page00023-3240-15 155,152 Rx · $3,055,508
2 bottles00023-3240-01 No Medicaid data
1 bottle00023-3240-02 No Medicaid data
1 bottle00023-3240-03 No Medicaid data
Drug total (last 4 qtrs): 155,152 Rx · 2,438,608 units · $3,055,508 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 00023-3205-02 · Allergan, 00023-3348-07 · Allergan, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.